日本プロテオーム学会の皆さま
こ の た び International Journal of Proteomics で は 「 Proteomics-Based Disease
Biomarkers」と題して特集を組むことになりました。
プロテオーム解析の分野ではバイオマーカー開発は主要なトピックスであり、論文・学会において多くの発表が行われています。バイオマーカーは医療現場のみならず、創薬のプロセスにおいても重要であるとの認識から、さまざまな分野の研究者が開発に携わっており、学際的な研究テーマとなっています。同時に、研究体制の問題、技術開発の問題、実用化の問題など、多くの点で議論がつきないところであり、毎年のように新しい展開がみられています。
プロテオーム解析のアプローチでバイオマーカー開発を推進している方からの、オリジナル論文、総説などをお待ちしています。日本・アジア地域からの情報発信としてよい機会だと思いますので、御考慮いただければ幸いです。
International Journal of Proteomics で発表されている「Call for Papers」を添付しました。
どうかよろしくお願いします。
平成２３年１月２９日
近藤格
創薬プロテオーム研究分野
国立がん研究センター研究所

International Journal of Proteomics

Special Issue on
Proteomics-Based Disease Biomarkers
Call for Papers
Sequencing of the human genome has greatly impacted
the proteomics-based analysis of disease by providing aframework for understanding the proteome of diseased
cells, tissues, and biological fluids. There is much interestin applying proteomics technologies to discover processes
at the protein level that are involved in various diseases,
to uncover new biomarkers that correlate with the early
diagnosis of diseases and to accelerate the developmentof new therapeutic targets. New proteomics technologies
are being developed in order to facilitate both the highthroughput and high-sensitivity requirements of diseaserelated applications of proteomics. These innovative technologies have greatly enhanced our ability to separate andcharacterize complex protein mixtures. They have also aided
our ability to identify proteins with greater sensitivity,
thereby providing the groundwork for future scientificbreakthroughs and possibly providing the framework forthe development of personalized disease therapy. We invite
investigators to contribute original research articles as well
as review articles that will stimulate the continuing eﬀorts tounderstand disease subtypes at the protein level, the development of protein-based biomarkers for the early detectionof disease, the development of treatment modalities based
upon disease-specific protein biomarker signatures, and theprotein- biomarker-based evaluation of therapeutic eﬃcacy.
We are interested in articles that explore aspects of proteinbased biomarkers in humans and also in animal models ofdisease. Potential topics include, but are not limited to:• Protein-based signatures of disease subtypes, withemphasis on the expression of diﬀerent protein
biomarkers reflective of a given disease subtype• Protein-based biomarkers for the early detection ofdiseases, including potential disease-specific posttranslational modifications of proteins• Latest technologies for the elucidation of protein
signatures of disease, including autoantibodies• Role of protein biomarkers in the process of drug
development• Role of protein biomarkers in the evaluation oftherapeutic eﬃcacy• Role of protein biomarkers in predicting and monitor-ing side eﬀects of therapeutic intervention
Before submission authors should carefully read over thejournal’s Author Guidelines, which are located at http://www.hindawi.com/journals/ijpro/guidelines.html. Prospective
authors should submit an electronic copy of their complete
manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following
timetable:
Manuscript Due

June 1, 2011

First Round of Reviews

September 1, 2011

Publication Date

December 1, 2011

Lead Guest Editor
David E. Misek, Department of Surgery, University ofMichigan, Ann Arbor, MI, 48109, USA; dmisek@umich.edu
Guest Editors
Tadashi Kondo, Division of Pharmacoproteomics,
National Cancer Center Research Institute, 5-1-1 Tsukiji,
Chuo-ku, Tokyo 104-0045, Japan; takondo@ncc.go.jp
Mark W. Duncan, Division of Endocrinology, Metabolism
and Diabetes, School of Medicine, University of Colorado
Denver, Aurora, CO 80045 , USA; Obesity Research Center,College of Medicine, King Saud University, Riyadh, Saudi
Arabia; mark.duncan@ucdenver.edu

Hindawi Publishing Corporation
http://www.hindawi.com/